Overview

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer Triple-Negative Breast Cancer

Status:
Completed

Trial end date:
2020-03-11

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free survival (PFS) in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) previously treated with at least two systemic chemotherapy regimens for unresectable, locally advanced or metastatic disease, and without brain metastasis at baseline.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences
Immunomedics, Inc.

Treatments:

Capecitabine
Gemcitabine
Vinorelbine